What changed in this filing

/stocks — the workspaceLOADING

Item 1. Business

2022-10-31 compared with 2021-10-29 · 260 added, 246 removed, 41 unchanged (93% of the section changed)

This Annual Report on Form

10-K contains forward-looking statements based on expectations, estimates, and projections as of the date of this filing.

Actual results

may differ materially from those expressed in forward-looking statements.

See Item 1A of Part I—“Risk Factors.”

Odyssey Group International,

was formed as a Nevada corporation in March 2014.

Our principal executive offices are located at 2372 Morse Ave., Irvine, CA 92614.

This Annual Report on Form 10-K contains forward-looking

statements based on expectations, estimates, and projections as of the date of this filing.

Actual results may differ materially from

those expressed in forward-looking statements.

See Item 1A of Part I—“ Risk Factors .”

Odyssey Health, Inc.

was formed as a Nevada

corporation in March 2014.

Our principal executive offices are located at 2300 West Sahara Avenue, Suite 800 - #4012, Las Vegas,

Nevada, 89102.

The registration statement effectuating our initial public offering became effective in July 2015.

Our shares of common stock

are listed on the OTCPink Marketplace (“OTC”) and there is currently very little public market for our common stock.

As used herein, when we refer

to “Odyssey”, “ODYY,”

the “Company,”

“our Company,”

“we,”

“us”

and “our,”

we mean Odyssey Group International, Inc., a Nevada corporation, unless the context indicates otherwise.

Odyssey is a publicly held

holding company with an emphasis on the development and acquisition of medical products and health related technologies.

We are focused

on developing and acquiring technologies that have a technological advantage and a substantial market opportunity within significant target

markets across the globe.

The corporate mission is to create or acquire distinct technologies and intellectual property with an emphasis

on acquisition targets that will generate positive cash flow.

Our strategic mission is to deliver financial results, which yield high

rates of returns for our shareholders and partners.

Our leadership team has significant experience and capabilities to commercialize our

technologies and submit to the appropriate regulatory agencies for marketing approval.

Our business model is to develop or acquire unique medical related products, engage

third parties to manufacture such products and then distribute the products through various distribution channels, including third parties.

We are developing potentially life-saving technologies:

the CardioMap®

Our shares of common stock are listed on the OTCPink

Marketplace (“OTC”) and there is currently very little public market for our common stock.

As used herein, when we refer to “Odyssey”,

“ODYY,” the “Company,” “our Company,” “we,” “us” and “our,” we

mean Odyssey Health, Inc., a Nevada corporation, unless the context indicates otherwise.

Odyssey is a publicly held holding company focused

on acquiring and developing medical products.

We are developing technologies that have a technological advantage, superior clinical utility,

and a substantial market opportunity within significant target markets across the globe.

The corporate mission is to create or acquire

distinct technologies and intellectual property with an emphasis on acquisition targets that will generate positive cash flow.

Our leadership

team has significant experience and capabilities to commercialize our technologies and submit them to the appropriate regulatory agencies

for marketing approval.

Our business model is to develop or acquire unique

medical-related products, engage third parties to assist in the development and manufacturing of such products, and then distribute the

products through various distribution channels, including third parties.

We own potentially life-saving technologies:

the CardioMap®

heart monitoring and screening device;

the Save A Life choking

rescue device;

PRV-001 and PRV-002 which are unique neurosteroid drug compounds intended to treat concussions and rare brain disorders.

To date, none of our product candidates has received regulatory clearance or approval for commercial sale.

We intend to acquire other

technologies and assets and plan to be a trans-disciplinary product development company involved in the development and commercialization

of products and technologies that may be applied over various medical markets.

We intend to license, improve

and/or develop our products and identify and select distribution channels.

We plan to establish agreements with distributors to get products

to market quickly as well as to undertake and engage in our own direct marketing efforts.

We will determine the most effective method

of distribution for each unique product that we include in our portfolio.

We intend to engage third

party research and development firms who specialize in the creation of medical products to assist us in the development.

We will apply

for trademarks and patents as we develop proprietary products.

the Save A Life choking rescue device;

and PRV-002 which is a unique neurosteroid drug compound

intended to treat mild traumatic brain injuries also known as concussions.

We on fifty percent of another unique neuro-steroid, PRV-001,

intended to treat rare brain disorders.

To date, none of our product candidates has received regulatory clearance or approval for commercial

We intend to acquire other technologies and assets

and plan to be a trans-disciplinary product development company involved in the development and commercialization of products and technologies

that may be applied over various medical markets.

We intend to license, improve and/or develop our

products and identify and select distribution channels.

We plan to establish agreements with distributors to get products to market quickly

as well as to undertake and engage in our own direct marketing efforts.

We will determine the most effective method of distribution for

each unique product that we include in our portfolio.

We intend to engage third party research and development

firms who specialize in the creation of medical products to assist us in the development.

We will apply for trademarks and patents as

we develop proprietary products.

Financial Information about Industry Segments

We do not report our financial

results by segment.

We do not report our financial results by segment.

See financial statements.

Our Growth Strategy

If the FDA clears or approves

our product candidates, we intend to enter into agreements with qualified distributors throughout the United States.

If the FDA clears or approves our product candidates

to be marketed commercially, we intend to enter into agreements with qualified distributors throughout the United States.

A similar approach

6 unchanged sentences

license agreements provide a stronger path to revenue and earnings than purely domestic products.

Our objective is to grow revenue

through marketing and sales of each of our product candidates, CardioMap®

and Save a Life, if they gain regulatory approvals.

no assurances can be given, management anticipates company growth from the following areas:

Our objective is to grow revenue through marketing

and sales of each of our product candidates, CardioMap® and Save a Life, and the two neuro-steroids, PRV-002 and PRV-001 if they gain

regulatory approvals.

Although no assurances can be given, management anticipates company growth from the following areas:

Distribution or License Agreements.

In most cases, we will enter into distribution agreements with

companies who have sales professionals with experience selling through a variety of sales methods.

These distribution agreements will

allow us to more quickly achieve sales and revenue in the health products industries.

2) Generate revenues from sales of CardioMap®

and Save a Life.

We intend to market

CardioMap®

and Save a Life through third party distributors and through our own efforts.

3) Identify and develop CardioMap®

for additional proprietary uses of the product.

pursue development of CardioMap®

technology for use in other areas of the human body, such as the brain, liver and kidney.

In most cases, we will enter into distribution agreements with companies who have sales professionals with experience selling through a variety of sales methods.

These distribution agreements will allow us to more quickly achieve sales and revenue in the health products industries.

Generate revenues from sales of CardioMap® and Save a Life.

When approved for sale by regulatory agencies we intend to market our products through third party distributors and through our own efforts.

Identify and develop our products for additional proprietary uses.

When funding allows, w e intend to pursue development of CardioMap® technology for use in other areas of the human body, such as the brain, liver and kidney.

We also intend to utilize our proprietary nasal delivery system to deliver other drugs to the brain to treat brain related medical issues.

The development and acquisition of new products.

We intend to pursue development and acquisition

of other product candidates and market any new products, if cleared or approved.

We intend, as capital resources permit, to develop such

opportunities if and when they present themselves.

We intend to pursue development and acquisition of other product candidates and market any new products, if cleared or approved.

We intend, as capital resources permit, to develop such opportunities if and when they present themselves.

Seek partners to assist in the further development of our drug device combination products.

intend to seek partners to assist with the further development and clinical trials of both PRV-001 and PRV-002.

Partnerships could be

in the form of government grants or from industry pharmaceutical companies who have an interest in brain related drug therapies.

We currently have no products

authorized for commercial distribution in either the United States, Europe or any other country.

We are developing devices and pharmaceutical

drugs, which are in various stages of development, and which will require regulatory clearance or approvals and we cannot begin marketing

and selling our product candidates until we obtain applicable authorizations from the respective regulatory agency.

FDA clearance or approval

to market the products will be required to sell in the United States.

About CardioMap®

The CardioMap®

is intended to be a heart monitoring and screening device based on a novel method of Dispersion Mapping in ECG analysis for the early,

non-invasive testing for coronary heart disease (“CHD”).

The heart monitoring system is intended to provide high quality 3-D

visualization and diagnosis of the heart using advanced signal analysis.

The product is being designed for use in a professional setting

or in remote settings including in-home use.

We have exclusive, royalty free rights to USPTO patent number 7,519,416 B2 related to the

CardioMap technology.

FDA cleared or approved, CardioMap®

could provide a better level of diagnosis with its improved sensitivity levels that can detect early warning signs that would normally

be invisible with standard ECG devices.

The system can dramatically cut the costs associated with the detection of ischemic heart disease

and will prove to be an invaluable testing device for cardiologists, physicians, clinics, hospitals, the fitness industry, sports teams,

emergency facilities and general public.

CardioMap®

was developed by VE Science Technology LLC, from whom we have purchased the product

We have a working model of the device and associated software and plan to further develop the technology for clinical trials and

a 510K FDA submission.

To sell, market and distribute the CardioMap®

product, clearance or approval from the FDA is required.

clearance or approval has not been obtained at this time.

We intend to seek partners to assist with the further development and clinical trials of both PRV-001 and PRV-002.

Partnerships could be in the form of government grants or from industry pharmaceutical companies who have an interest in brain related drug therapies.

We currently have no products authorized for commercial

distribution in either the United States, Europe or any other country.

We have development programs for devices and pharmaceutical drugs,

which are in various stages of development.

Currently we are only funding the development of PRV-002 intended to treat concussion.

to funding constraints and market conditions the CardiMap ® and the choking rescue device programs have been suspended.

All of our products require regulatory clearance or approvals and we cannot begin marketing and selling our product candidates until we

obtain applicable authorizations from the respective regulatory agency.

FDA clearance or approval to market the products will be required

to sell in the United States.

About CardioMap®

The CardioMap® System is intended to be a

heart monitoring and screening device based on a novel method of Dispersion Mapping in ECG analysis for the early, non-invasive testing

for coronary heart disease (“CHD”).

The heart monitoring system is intended to provide high quality 3-D visualization and

diagnosis of the heart using advanced signal analysis.

The product is being designed for use in a professional setting or in remote settings

including in-home use.

We have exclusive, royalty free rights to USPTO patent number 7,519,416 B2 related to the CardioMap technology.

FDA cleared or approved, CardioMap® could

provide a better level of diagnosis with its improved sensitivity levels that can detect early warning signs that would normally be invisible

with standard ECG devices.

The system could dramatically cut the costs associated with the detection of ischemic heart disease and will

prove to be an invaluable testing device for cardiologists, physicians, clinics, hospitals, the fitness industry, sports teams, emergency

facilities and general public.

CardioMap® was developed by VE Science Technology LLC, from whom we have purchased the product rights.

We have a working model of the device and associated software and plan to further develop the technology for clinical trials and a 510K

FDA submission when funding is secured.

To sell, market and distribute the CardioMap® product, clearance or approval from the FDA

Such clearance or approval has not been obtained at this time.

Product Development Plan:

2 unchanged sentences

FDA Submission

This product development plan

is an estimate and is subject to change based on funding, technical risks and regulatory approvals.

About Save-a-Life®

In July of 2019 we purchased

all intellectual property including two patents for the choking rescue device:

This product development plan is an estimate only.

The Product Development Plan is subject to change based on our ability to fund the program, technical risks and regulatory approvals.

About Save-a-Life®

In July 2019, we purchased all intellectual property

including two patents for the choking rescue device:

patent Number RE45, 535 E, and patent Number 8,454,624 B2.

The Save a Life®

(“SAL”) choking rescue device is currently in development and being designed to be a safe, and easy to

use device for removing a lodged mass from the throat of a choking victim.

The device includes a pump for creating a vacuum chamber, which

is connected seamlessly with a replaceable/disposable mouthpiece.

In an emergency the SAL may be easily inserted into the victim’s

mouth, which depresses the tongue providing a clear application.

By pressing an activation button on the device, the internal pump is

intended to deliver the appropriate amount of instantaneous vacuum to dislodge the mass without harm or damage to the person.

The application

is intended to be instantly effective as the device will be operational and effective in a matter of seconds.

To sell, market and distribute

the Save-a-Life product, clearance or approval from the FDA is required.

Clinical trials for the device will be conducted on anatomically

correct models to demonstrate device performance.

The regulatory pathway is expected to be a 510k submission to the FDA once successful

clinical data is obtained.

FDA clearance or approval has not been obtained at this time.

The Save a Life® (“SAL”)

choking rescue device is currently in development and is designed to be a safe, and easy-to-use device for removing a lodged mass from

the throat of a choking victim.

The device includes a pump for creating a vacuum chamber, which is connected seamlessly with a replaceable/disposable

In an emergency, the SAL may be easily inserted into the victim’s mouth, which depresses the tongue providing a clear

By pressing an activation button on the device, the internal pump is intended to deliver the appropriate amount of instantaneous

vacuum to dislodge the mass without harm or damage to the person.

The application is intended to be instantly effective as the device

will be operational and effective in a matter of seconds.

To sell, market and distribute the Save-a-Life product, clearance or approval

from the FDA is required.

Clinical trials for the device will be conducted on anatomically correct models to demonstrate device performance.

The regulatory pathway is expected to be a 510k submission to the FDA once successful clinical data is obtained.

FDA clearance or approval

has not been obtained at this time.

The Development Plan for the Save-a-Life is below.

3 unchanged sentences

FDA Submission

Product Development Plan is

an estimate only and is subject to change based on funding, technical risks and regulatory approvals.

This product development plan is an estimate only

and is subject to change based on funding, technical risks, the clinical pathway and regulatory approvals.

About the neurosteroid PRV-001

The neurosteroid, PRV-001,

is intended to improve function and lifespan in pediatric disorders where de-myelination and cell death is widespread in the cortex, subcortical

nuclei, brainstem and cerebellum regions of the brain.

The new chemical entity is designed to work through gene amplification to simultaneously

remove intra-neuronal debris while promoting antioxidant capacity and myelin repair/cell proliferation.

Disorders like Nieman Pick Type

C disease are multi-faceted in their pathology and require a treatment that can work at many levels to stop progression.

compound for the neurosteroid being developed has completed an initial safety study in rats.

Results of preclinical studies suggest that

PRV-001 may improve neuromotor, cognitive and mental performance.

To sell the PRV-001 neurosteroid, further development and clinical studies

are required.

PRV-001 will also require approval by the FDA in order to be sold in the United States.

Per our agreement with Prevacus,

a Tallahassee, Florida based biotech company, we have fifty percent ownership in the drug compound and associated intellectual property.

There are issued patents covering methods of PRV-001 synthesis.

Product Development Plan for

The neurosteroid, PRV-001, is intended to improve

function and lifespan in pediatric disorders where Central Nervous System (CNS) de-myelination and cell death is widespread in the cortex,

subcortical nuclei, brainstem, and cerebellar regions.

PRV-001, a new chemical entity, is designed to work through gene amplification

to simultaneously remove intra-neuronal debris while promoting antioxidant capacity and myelin repair/cell proliferation.

Disorders like

Nieman Pick Type C disease are multi-faceted in their pathology and require a treatment that can work at many levels to stop progression.

The chemical compound for the neurosteroid being developed has completed an initial safety study in rats.

Results of preclinical studies

suggest that PRV-001 may improve neuromotor, cognitive and mental performance.

To market the PRV-001 neurosteroid, further development

and clinical studies are required.

PRV-001 will also require approval by the FDA to be sold in the United States.

Per our agreement with Prevacus, Inc.

a Tallahassee,

Florida based biotech company, we have fifty percent (50%) ownership in the drug compound and associated intellectual property.

agreement also called for a joint venture to be created by the two companies.

The term to create the joint venture has expired and a joint

venture is no longer planned.

The United States Patent and Trademark Office issued patents covering methods of PRV-001 synthesis.

Product Development Plan for PRV-001:

Pre-clinical Animal Studies

FDA Submission

This product development plan

is an estimate and is subject to change based on funding, technical risks and regulatory approvals.

This product development plan is an estimate and

is subject to change based on funding, technical risks and regulatory approvals.

About the neurosteroid PRV-002

On March 1, 2021, we purchased

On March 1, 2021, Odyssey Health, Inc.

one hundred percent (100%) of the drug compound PRV-002 from Prevacus, Inc.

1 unchanged sentence

being developed for the treatment of mTBI (concussion).

Results of preclinical studies suggest that PRV-002 has equivalent, and potentially

Results of preclinical studies suggest that PRV-002 has an equivalent, and potentially

superior, neuroprotective effects compared to related neurosteroids.

In animal models of concussion PRV-002 reduced the behavioral pathology

associated with brain injury symptoms such as short-term memory loss, depression/anxiety-like behavior and motor-sensory impairment.

drug is administered through the nasal passage from a novel device.

PRV-002 is lipophilic and can cross the blood-brain barrier thus supporting

its potential to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow through

gene amplification.

The drug has completed toxicology

studies in rat and dog.

Studies show that PRV-002 has a safety margin over 200X it’s predicted efficacious dose.

PRV-002 to date

has been shown to be stable up to 104 degrees for 6-months.

The drug candidate is currently being spray-dry manufactured into a powder

that will be filled into the novel breath-propelled nasal device developed by Odyssey.

The device is light weight and easy to use in the

Odyssey’s novel nasal device is breath-propelled causing the soft palate to close in the back of the nasopharynx.

This mechanism

traps PRV-002 in the nasal cavity allowing for a more abundant and faster drug availability in the traumatized brain.

Safety studies have

established a dosing regimen of 2X/day for fourteen (14) days.

Clinical Trial Phase I is site-set in Melbourne, Australia with a Contract

Research Organization (CRO), Nucleus Network Inc.

The country of Australia provides a twenty percent (20%) currency exchange advantage

and a 43.5% rebate at the end of our fiscal year from the Australian government on all Research and Development performed in Australia.

The trial is expected to begin in November 2021.

A comprehensive Investigator’s

Brochure has been created and submitted to the Alfred Ethics Committee by our CRO in Australia.

Approval has been granted to initiate

the phase 1 human trial and subjects have been enrolled.

The phase 1 trial will have two components to it, phase 1a and 1b.

designed to determine the safety profile of the drug in healthy human subjects.

Phase 1a will have forty-eight subjects using a Single

Ascending/Multiple Ascending (SAD/MAD) drug administration design.

For both the SAD and MAD portions there will be 4 groups, placebo,

low dose, middle dose and high dose.

All dosages are within the animal preclinical efficacy and safety range.

The SAD component is a 1X

treatment and the MAD component is a 1X/day treatment for 5-days.

Blood and urine samples will be collected at multiple time points for

safety pharmacokinetics.

Standard safety monitoring will be provided for each bodily system.

Phase 1b will begin following the completion

of the final safety report from Phase 1a establishing no safety concerns.

In Phase 1b PRV-002 will be administered to 24 acutely-concussed

patients, 2x a day for 14-days.

The trial will be low powered and evaluate safety as well as efficacy measurements to be used in Phase

2/3 clinical trials.

Based on the Phase 1a and 1b data we plan to submit an application for an Investigational New Drug with the FDA and

conduct a phase 2 trial in the United States.

Patents on PRV-002 have been

filed and/or issued:

In animal models of mild brain injury PRV-002 reduced the behavioral

pathology associated with brain injury symptoms such as short-term memory loss, depression/anxiety-like behavior, and motor-sensory impairment.

The drug is administered through the nasal passage from a novel device.

PRV-002 is lipophilic and can cross the blood-brain barrier thus

supporting its potential to rapidly eliminate swelling, oxidative stress, and inflammation in the brain while restoring proper blood flow

through gene amplification.

The drug has completed toxicology studies in rat

Studies show that PRV-002 has a safety margin over 200X its predicted efficacious dose.

PRV-002 to date has been shown to be

stable up to 104 degrees for 18-months.

The drug candidate is spray-dry manufactured into a powder and filled into the intranasal device.

The device is lightweight and easy to use in the field.

Odyssey’s novel intranasal device is breath-propelled causing the soft palate

to close in the back of the nasopharynx.

This mechanism traps PRV-002 in the nasal cavity allowing for a more abundant and faster drug

availability in the traumatized brain.

Safety studies have established a dosing regimen of 2X/day for fourteen (14) days.

clinical trial was performed in Melbourne, Australia with a Contract Research Organization (CRO), Avance Clinical Pty Ltd and Nucleus

Network Pty Ltd.

The country of Australia provides a greater than twenty six percent (26%) currency exchange advantage and a forty-three

and one half percent (43.5%) rebate at the end of our fiscal year from the Australian government on all Research and Development performed

in Australia.

A comprehensive Investigator’s Brochure

was created and approved by the Alfred Ethics Committee by Odyssey Health’s CRO in Australia.

Phase 1 was designed to determine

the safety profile of the drug in healthy human subjects.

It was double-blinded, randomized and placebo controlled (3:1, drug:

Phase 1 used a Single Ascending/Multiple Ascending (SAD/MAD) drug administration design.

The SAD component was a 1X treatment (low, medium,

or high dose) and the MAD component was a 1X/day treatment for five (5) consecutive days (low and medium dose).

Blood and urine samples

were collected at multiple time points for safety pharmacokinetics.

Standard safety monitoring was provided for each body system.

Forty (40) human subjects (31 males, 9 females)

were successfully enrolled in Phase I.

The Safety Review Board, made up of medical doctors, has reviewed the trial data and has determined

the drug is safe and well tolerated at all dosing levels.

In Phase II clinical trial, PRV-002 will be administered

to acutely concussed patients, 2x a day for fourteen (14) days.

Based on the Phase I data, we plan to apply for an Investigational New

Drug application with the FDA and conduct a Phase II trial in the United States.

Patents on PRV-002 have been filed and/or issued

and a patent has been filed on the nasal delivery device:

Composition of matter for PRV-002 and analogs

1 unchanged sentence

Synthetic methods for PRV-002

Development Plan

Product Development Plan:

Pre-clinical Animal Studies

Food and Drug

Administration Submission

September 2021

This product development plan

is an estimate and is subject to change based on funding, technical risks and regulatory approvals.

We believe that the primary

competition for our products and services is from existing companies offering EKG equipment and anti-choking devices, as well as other

pharmaceutical companies engaged in the development of Orphan drugs.

FDA Submission

December 2023

February 2025

This product development plan is an estimate and

is subject to change based on funding, technical risks and regulatory approvals.

We believe that the primary competition for our

products and services is from existing companies offering EKG equipment and anti-choking devices, as well as other pharmaceutical companies

engaged in the development of Orphan drugs.

SAL Competitive Analysis

The Dechoker is a device that can be used for

choking first aid on anyone 12 months or older, regardless of illness, disorder or other health-related condition.

It utilizes a hand

powered pump system to extract blockages.

LifeVac is designed with a valve to prevent any

air from exiting through the mask.

This designed valve prevents air from pushing food or objects downward.

This creates a one-way suction

to remove the lodged food or object.

Act+Fast Heimlich maneuver training vests

Act+Fast™ Anti-Choking Trainer, Blue (AHA),

This device enables students to develop confidence in their ability to perform the Abdominal Thrust (Heimlich) Maneuver as recommended

by the American Heart Association (AHA).

It has been designed to be realistic and easy to use.

CardioMap® Competitive Analysis

Note, none of the current rapid EKG devices have

the ability to digitally map the heart.

Each of the below competitors give EKG read outs only.

CardioResting (Nasiff)

The CardioResting ECG is the first complete and

full-featured 12 lead PC based cardiology system.

The ECG is durable, reliable and easy to learn.

Performs and manages tests while saving

money and working with your existing equipment.

Our system is EMR compatible with an unlimited database.

Welch Allyn PC Based Electrocardiograph

Automatically transfer patient information and

test data into most EMRs without redundant work steps, misidentified patients, or delays from copying, scanning and shredding ECG reports.

QardioCore is a wireless medical grade ambulatory

ECG monitor system that can identify atrial fibrillation and other arrhythmias.

No wires, gels or patches are required.

No in-clinic fitting

nor technician needed - QardioCore is 100% deployed remotely.

Governmental Regulation

Product Regulation

The processing,

formulation, safety, manufacturing, packaging, labeling, advertising and distribution of our products may be subject to certain regulation

by one or more federal agencies, including the FDA, Housing and Human Services (the “HHS”), the Federal Trade Commission (the

“FTC”), the Consumer Product Safety Commission (the “CPSC”), the United States Department of Agriculture (the

“USDA”) and the Environmental Protection Agency (the “EPA”), and by various agencies of the states and localities

in which our products are sold.

To sell, market and distribute

the CardioMap®, the Save a Life or the drug compound products, clearance or approval from the FDA is required.

Such clearance or approval

has not been obtained at this time and our products are not currently available for commercial sale.

we eventually sell in foreign countries are also subject to regulation under various national, local and international laws that include

provisions governing, among other things, the formulation, manufacturing, packaging, labeling, advertising and distribution of drugs

and medical products.

Government regulations in foreign countries may prevent or delay the introduction, or require the reformulation,

of some of our products.

At the date hereof, we have

four employees and intend to hire additional employees in the foreseeable future.

The processing, formulation, safety, manufacturing,

packaging, labeling, advertising and distribution of our products may be subject to certain regulation by one or more federal agencies,

including the FDA, Housing and Human Services (the “HHS”), the Federal Trade Commission (the “FTC”), the Consumer

Product Safety Commission (the “CPSC”), the United States Department of Agriculture (the “USDA”) and the Environmental

Protection Agency (the “EPA”), and by various agencies of the states and localities in which our products are sold.

To sell, market and distribute the CardioMap®,

the Save a Life or the drug compound products, clearance or approval from the FDA is required.

Such clearance or approval has not been

obtained at this time and our products are not currently available for commercial sale.

Any products we eventually sell in foreign countries

are also subject to regulation under various national, local and international laws that include provisions governing, among other things,

the formulation, manufacturing, packaging, labeling, advertising and distribution of drugs and medical products.

Government regulations

in foreign countries may prevent or delay the introduction, or require the reformulation, of some of our products.

At the date hereof, we have four employees and

do not intend to hire additional employees in the foreseeable future.

Where you can find more information

Our Annual Report on Form

10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to reports filed pursuant to Sections 13(a) and 15(d)

of the Securities Exchange Act of 1934, as amended (“Exchange Act”), are filed with the U.S.

Securities and Exchange Commission

(the “SEC”).

Such reports and other information filed by us with the SEC are available free of charge on our website

at http://www.odysseygi.com when such reports are available on the SEC website.

The public may read and copy any materials filed

by us with the SEC at the SEC’s Public Reference Room at 100 F Street, NE, Room 1580, Washington, DC 20549.

The public may obtain

information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330.

The SEC maintains an Internet site that

contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC at www.sec.gov.

The contents of these websites are not incorporated into this filing.

Further, our references to the URLs for these websites are intended

to be inactive textual references only.

Our Annual Report on Form 10-K, Quarterly Reports

on Form 10-Q, Current Reports on Form 8-K, and amendments to reports filed pursuant to Sections 13(a) and 15(d) of the Securities Exchange

Act of 1934, as amended (“Exchange Act”), are filed with the U.S.

Securities and Exchange Commission (the “SEC”).

Such reports and other information filed by us with the SEC are available free of charge on our website at http://www.odysseyhealthinc.com when

such reports are available on the SEC website.

The public may read and copy any materials filed by us with the SEC at the SEC’s

Public Reference Room at 100 F Street, NE, Room 1580, Washington, DC 20549.

The public may obtain information on the operation of the

Public Reference Room by calling the SEC at 1-800-SEC-0330.

The SEC maintains an Internet site that contains reports, proxy and information

statements and other information regarding issuers that file electronically with the SEC at www.sec.gov.

The contents of these websites

are not incorporated into this filing.

Further, our references to the URLs for these websites are intended to be inactive textual references

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 1. Business